Abstract
Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss. There is also evidence of potential compensatory responses in DS that benefit the brain and delay the onset of dementia after there is sufficient neuropathology for a diagnosis of AD. This review describes some of the existing literature and also highlights gaps in our knowledge regarding AD neuropathology in DS. It will be critical in the future to develop networked brain banks with standardized collection procedures to fully characterize the regional and temporal pathological events associated with aging in DS. As more information is acquired regarding AD evolution in DS, there will be opportunities to develop interventions that are age-appropriate to delay AD in DS.
Keywords: Beta-amyloid, neurofibrillary tangles, neuroinflammation, oxidative damage, posttranslational modifications, senile plaques, trisomy 21, vascular pathology, white matter damage.
Current Alzheimer Research
Title:Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Volume: 13 Issue: 1
Author(s): Elizabeth Head, Ira T. Lott, Donna M. Wilcock and Cynthia A. Lemere
Affiliation:
Keywords: Beta-amyloid, neurofibrillary tangles, neuroinflammation, oxidative damage, posttranslational modifications, senile plaques, trisomy 21, vascular pathology, white matter damage.
Abstract: Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss. There is also evidence of potential compensatory responses in DS that benefit the brain and delay the onset of dementia after there is sufficient neuropathology for a diagnosis of AD. This review describes some of the existing literature and also highlights gaps in our knowledge regarding AD neuropathology in DS. It will be critical in the future to develop networked brain banks with standardized collection procedures to fully characterize the regional and temporal pathological events associated with aging in DS. As more information is acquired regarding AD evolution in DS, there will be opportunities to develop interventions that are age-appropriate to delay AD in DS.
Export Options
About this article
Cite this article as:
Head Elizabeth, T. Lott Ira, M. Wilcock Donna and A. Lemere Cynthia, Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology, Current Alzheimer Research 2016; 13 (1) . https://dx.doi.org/10.2174/1567205012666151020114607
DOI https://dx.doi.org/10.2174/1567205012666151020114607 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer’s Disease Treatment
CNS & Neurological Disorders - Drug Targets MicroRNA Dysregulation in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Clinical Significance of Umami Taste and Umami-Related Gene Expression Analysis for the Objective Assessment of Umami Taste Loss
Current Pharmaceutical Design Aging is Not a Disorder
Current Aging Science Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry Tau Therapeutic Strategies for the Treatment of Alzheimers Disease
Current Topics in Medicinal Chemistry Alzheimers Disease and P300: Review and Evaluation of Task and Modality
Current Alzheimer Research Applications of Arterial Spin Labelling in Mild Cognitive Impairment, Alzheimers Disease and Other Forms of Dementia
Current Medical Imaging Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Current Pharmaceutical Design Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research Evidence for Predominance of CCR5-Using HIV-1 Strains During Highly Active Antiretroviral Therapy
Current HIV Research Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets The Role of Monocytes and Macrophages in the Pathogenesis of HIV-1 Infection
Current Medicinal Chemistry Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview
Current Clinical Pharmacology Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets